These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36299884)

  • 21. Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases.
    Kaur A; Sharma S
    Inflammopharmacology; 2017 Jun; 25(3):293-312. PubMed ID: 28417246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PDGF receptor-β uses Akt/mTORC1 signaling node to promote high glucose-induced renal proximal tubular cell collagen I (α2) expression.
    Das F; Ghosh-Choudhury N; Venkatesan B; Kasinath BS; Ghosh Choudhury G
    Am J Physiol Renal Physiol; 2017 Aug; 313(2):F291-F307. PubMed ID: 28424212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TBK1-mTOR Signaling Attenuates Obesity-Linked Hyperglycemia and Insulin Resistance.
    Bodur C; Kazyken D; Huang K; Tooley AS; Cho KW; Barnes TM; Lumeng CN; Myers MG; Fingar DC
    Diabetes; 2022 Nov; 71(11):2297-2312. PubMed ID: 35983955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mammalian target of rapamycin and the kidney. I. The signaling pathway.
    Lieberthal W; Levine JS
    Am J Physiol Renal Physiol; 2012 Jul; 303(1):F1-10. PubMed ID: 22419691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
    Hall BA; Kim TY; Skor MN; Conzen SD
    Breast Cancer Res Treat; 2012 Sep; 135(2):469-79. PubMed ID: 22842983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
    Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
    Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypothalamic mTOR: the rookie energy sensor.
    Martínez de Morentin PB; Martinez-Sanchez N; Roa J; Ferno J; Nogueiras R; Tena-Sempere M; Dieguez C; Lopez M
    Curr Mol Med; 2014 Jan; 14(1):3-21. PubMed ID: 24236459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
    Ravichandran K; Zafar I; Ozkok A; Edelstein CL
    Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling.
    Zhang C; Wendel AA; Keogh MR; Harris TE; Chen J; Coleman RA
    Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1667-72. PubMed ID: 22307628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mTOR complex-2 activates ENaC by phosphorylating SGK1.
    Lu M; Wang J; Jones KT; Ives HE; Feldman ME; Yao LJ; Shokat KM; Ashrafi K; Pearce D
    J Am Soc Nephrol; 2010 May; 21(5):811-8. PubMed ID: 20338997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c.
    Hagiwara A; Cornu M; Cybulski N; Polak P; Betz C; Trapani F; Terracciano L; Heim MH; Rüegg MA; Hall MN
    Cell Metab; 2012 May; 15(5):725-38. PubMed ID: 22521878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring mammalian target of rapamycin (mTOR) activity.
    Ikenoue T; Hong S; Inoki K
    Methods Enzymol; 2009; 452():165-80. PubMed ID: 19200882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling.
    Yoon MS
    Nutrients; 2017 Oct; 9(11):. PubMed ID: 29077002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphoenolpyruvate carboxykinase in urine exosomes reflect impairment in renal gluconeogenesis in early insulin resistance and diabetes.
    Sharma R; Kumari M; Prakash P; Gupta S; Tiwari S
    Am J Physiol Renal Physiol; 2020 Mar; 318(3):F720-F731. PubMed ID: 32036699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current development of the second generation of mTOR inhibitors as anticancer agents.
    Zhou HY; Huang SL
    Chin J Cancer; 2012 Jan; 31(1):8-18. PubMed ID: 22059905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.
    Soliman GA; Acosta-Jaquez HA; Dunlop EA; Ekim B; Maj NE; Tee AR; Fingar DC
    J Biol Chem; 2010 Mar; 285(11):7866-79. PubMed ID: 20022946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells.
    Sini P; James D; Chresta C; Guichard S
    Autophagy; 2010 May; 6(4):553-4. PubMed ID: 20364113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
    Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Insights Into the Role of mTOR Signaling in the Cardiovascular System.
    Sciarretta S; Forte M; Frati G; Sadoshima J
    Circ Res; 2018 Feb; 122(3):489-505. PubMed ID: 29420210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.